Table 1 Selected characteristics of the cohort at baseline visit, summarised by study year and number of prior vaccinations
From: Antibody responses against influenza A decline with successive years of annual influenza vaccination
Overall | Number of prior vaccinations | ||||||||
|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | 4 | 5 | ||||
2020 | N = 595 | N = 52 | N = 71 | N = 69 | N = 67 | N = 75 | N = 261 | ||
Median age in years (IQR) | 39 (31, 48) | 39 (30, 52) | 39 (31, 47) | 39 (29, 47) | 36 (28, 44) | 36 (30, 47) | 42 (32, 50) | ||
Sex | |||||||||
Female | 483 (81%) | 40 (77%) | 59 (83%) | 59 (86%) | 52 (78%) | 62 (83%) | 211 (81%) | ||
Male | 110 (19%) | 12 (23%) | 12 (17%) | 10 (14%) | 14 (21%) | 13 (17%) | 49 (19%) | ||
Other | 1 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.5%) | 0 (0%) | 0 (0%) | ||
Median BMI (IQR) | 24.2 (21.7, 27.8) | 22.5 (20.8, 25.6) | 24.5 (22.7, 27.2) | 23.5 (21.2, 27.3) | 23.7 (21.1, 27.6) | 24.7 (21.9, 29.2) | 24.5 (22.1, 28.0) | ||
Has at least 1 health condition | 80 (13%) | 6 (12%) | 6 (8.5%) | 9 (13%) | 7 (10%) | 5 (6.7%) | 47 (18%) | ||
Provides direct clinical care | 339 (57%) | 15 (29%) | 38 (54%) | 43 (62%) | 30 (45%) | 49 (66%) | 164 (63%) | ||
Occupation group | |||||||||
Clinical | 315 (53%) | 15 (29%) | 31 (44%) | 34 (49%) | 28 (42%) | 44 (59%) | 163 (63%) | ||
Laboratory | 30 (5.1%) | 2 (3.8%) | 4 (5.7%) | 4 (5.8%) | 4 (6.1%) | 1 (1.4%) | 15 (5.8%) | ||
Administrative | 75 (13%) | 9 (17%) | 11 (16%) | 8 (12%) | 10 (15%) | 10 (14%) | 27 (10%) | ||
Allied health | 63 (11%) | 6 (12%) | 11 (16%) | 13 (19%) | 11 (17%) | 3 (4.1%) | 19 (7.3%) | ||
Research | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Other | 108 (18%) | 20 (38%) | 13 (19%) | 10 (14%) | 13 (20%) | 16 (22%) | 36 (14%) | ||
Vaccine brand | |||||||||
GSK | 219 (37%) | 14 (27%) | 35 (50%) | 25 (36%) | 27 (40%) | 29 (39%) | 89 (34%) | ||
Sanofi | 210 (35%) | 17 (33%) | 23 (33%) | 28 (41%) | 25 (37%) | 26 (35%) | 91 (35%) | ||
Seqirus | 165 (28%) | 21 (40%) | 12 (17%) | 16 (23%) | 15 (22%) | 20 (27%) | 81 (31%) | ||
2021 | N = 1,031 | N = 15 | N = 55 | N = 81 | N = 115 | N = 137 | N = 628 | ||
Median age in years (IQR) | 40 (32, 50) | 26 (21, 36) | 34 (27, 52) | 35 (28, 47) | 37 (27, 48) | 38 (30, 46) | 43 (35, 51) | ||
Sex | |||||||||
Female | 874 (85%) | 9 (60%) | 47 (85%) | 69 (85%) | 96 (83%) | 121 (88%) | 532 (85%) | ||
Male | 155 (15%) | 6 (40%) | 8 (15%) | 12 (15%) | 19 (17%) | 16 (12%) | 94 (15%) | ||
Other | 2 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.3%) | ||
Median BMI (IQR) | 25.1 (22.3, 29.3) | 24.0 (22.3, 26.5) | 23.2 (20.8, 26.9) | 23.9 (22.1, 26.1) | 24.9 (22.0, 29.4) | 24.9 (22.5, 28.7) | 25.5 (22.5, 29.5) | ||
Has at least 1 health condition | 152 (15%) | 3 (20%) | 6 (11%) | 10 (12%) | 12 (10%) | 15 (11%) | 106 (17%) | ||
Provides direct clinical care | 473 (46%) | 1 (6.7%) | 14 (25%) | 27 (34%) | 49 (43%) | 61 (45%) | 321 (51%) | ||
Occupation group | |||||||||
Clinical | 473 (46%) | 1 (6.7%) | 14 (25%) | 27 (34%) | 49 (43%) | 61 (45%) | 321 (51%) | ||
Laboratory | 55 (5.3%) | 1 (6.7%) | 2 (3.6%) | 3 (3.8%) | 8 (7.0%) | 6 (4.4%) | 35 (5.6%) | ||
Administrative | 137 (13%) | 4 (27%) | 6 (11%) | 14 (18%) | 19 (17%) | 20 (15%) | 74 (12%) | ||
Allied health | 119 (12%) | 1 (6.7%) | 3 (5.5%) | 6 (7.5%) | 14 (12%) | 15 (11%) | 80 (13%) | ||
Research | 144 (14%) | 3 (20%) | 17 (31%) | 21 (26%) | 13 (11%) | 24 (18%) | 66 (11%) | ||
Other | 101 (9.8%) | 5 (33%) | 13 (24%) | 9 (11%) | 12 (10%) | 11 (8.0%) | 51 (8.1%) | ||
Vaccine brand | |||||||||
GSK | 4 (0.4%) | 1 (7.1%) | 1 (1.8%) | 1 (1.3%) | 0 (0%) | 1 (0.7%) | 0 (0%) | ||
Sanofi | 885 (87%) | 13 (93%) | 53 (96%) | 74 (93%) | 108 (96%) | 123 (90%) | 514 (83%) | ||
Seqirus | 131 (13%) | 0 (0%) | 1 (1.8%) | 5 (6.3%) | 5 (4.4%) | 12 (8.8%) | 108 (17%) | ||
